Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

– Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial – Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into 2025 – All-stock merger of equals transaction with...

Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

– Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial – Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into 2025 – All-stock merger of equals transaction with...

Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company

ISS states in its Aeterna Zentaris FOR recommendation that “on balance, the deal has strong strategic merit, third party solicitation was unable to generate any other actionable proposals, and governance conflicts appear to have been reasonably...